Mast cell membrane stabilizer

"Mast cell membrane stabilizer" does **not refer to a single identifiable molecule, receptor, or protein, but rather to a pharmacological class of therapeutic agents that function to stabilize mast cell membranes, thereby preventing the release of preformed mediators such as histamine, leukotrienes, and cytokines. The therapeutic effect is achieved mostly by inhibiting calcium influx required for mast cell degranulation, and by interfering with various signaling pathways connected to mast cell activation[1][2][3][4][5][6][7]. Drugs in this class are used primarily for allergic and inflammatory diseases, including asthma, allergic rhinitis, and mastocytosis. The term should not be used as a molecular or receptor target, but rather as a functional drug class descriptor. **Note:** - This entry is considered **incorrect** as a therapeutic target because "Mast cell membrane stabilizer" is not a specific molecule or receptor, but a mechanistic drug class encompassing multiple different molecular targets (e.g., ion channels, signaling proteins, surface receptors)[1][2][3][4]. - For structured data, therapeutic targets should be specific molecules (e.g., "High-affinity IgE receptor FcεRI," "Spleen tyrosine kinase (SYK)," "Calcium channel on mast cell membrane"), not broad pharmacological mechanisms or drug classes.

Other names

Mast cell stabilizerMast cell membrane stabilizing agentMC stabilizerMast cell stabilizing drug

Inhibition of Ca²⁺ influx into mast cells, stabilizing the cell membrane and preventing degranulation[1][2][3][4][5][6] - Blockade of IgE-regulated calcium channels[4] - Interference with Cl⁻ and K⁺ channels affecting membrane potential and Ca²⁺ entry[1] - Inhibition of intracellular signaling and phosphorylation cascades leading to mediator release[1][2][3] - Inhibition of lipid raft formation and disruption of signaling apparatus (e.g., TF002)[7]